BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36274363)

  • 1. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3K27 methylation and H3S28 phosphorylation-dependent transcriptional regulation by INHAT subunit SET/TAF-Iβ.
    Kim JY; Kim KB; Son HJ; Chae YC; Oh ST; Kim DW; Pak JH; Seo SB
    FEBS Lett; 2012 Sep; 586(19):3159-65. PubMed ID: 22796192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
    Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
    Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of EZH1 and EZH2 in development and cancer.
    Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
    BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
    Gautam N; Kaur M; Kaur S
    J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
    Mu W; Starmer J; Yee D; Magnuson T
    Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
    Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
    BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INHAT subunit SET/TAF-Iβ regulates PRC1-independent H2AK119 mono-ubiquitination via E3 ligase MIB1 in colon cancer.
    Park J; Kim JY; Park JW; Kang JY; Oh H; Hahm JY; Chae YC; Chakravarti D; Seo SB
    NAR Cancer; 2023 Sep; 5(3):zcad050. PubMed ID: 37746636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The noncanonical role of EZH2 in cancer.
    Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
    Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
    Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
    Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
    Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
    Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
    Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
    J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
    Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
    Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
    Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
    Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.